Union Health Minister JP Nadda spearheaded the launch of an indigenous Tetanus and Adult Diphtheria (TD) vaccine at Kasauli’s Central Research Institute, heralding a new era of self-reliant vaccine production in India. This pioneering effort by CRI represents a breakthrough in domestic biotechnology.
At the event, Nadda termed it a ‘game-changer’ for public health systems, applauding the institute’s team and framing it within the Atmanirbhar Bharat framework. He revealed that this vaccine has propelled India to 99% vaccination coverage, a remarkable accomplishment viewed globally as a health revolution.
CRI plans to provide 5.5 million doses to the Universal Immunization Programme through April 2026, with intentions to expand manufacturing capacity. Praising PM Modi’s directives, Nadda noted the collaborative push by states to realize health sector autonomy.
Reaffirming India’s role as the ‘pharmacy of the world’ and its third-place WHO ranking, Nadda highlighted rapid innovations: contrasting prolonged historical developments—like 30 years for TB drugs—with COVID-19, where India rolled out two vaccines in nine months and over 220 crore doses digitally.
This initiative not only secures vital immunizations but also enhances India’s strategic position in global health security, paving the way for more indigenous innovations.